NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis → 25% of Americans Are In Grave Danger (From Banyan Hill Publishing) (Ad) Free NLSP Stock Alerts $0.13 0.00 (-3.09%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.1852-Week Range$0.11▼$1.53Volume188,896 shsAverage Volume602,788 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get NLS Pharmaceutics alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About NLS Pharmaceutics Stock (NASDAQ:NLSP)NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More NLSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLSP Stock News HeadlinesMay 29, 2024 | americanbankingnews.comNLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Up 182.0% in MayMay 28, 2024 | stockhouse.comNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelMay 24, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finance.yahoo.comNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 14, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 11, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceMarch 11, 2024 | finance.yahoo.comNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing ComplianceFebruary 23, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqFebruary 14, 2024 | seekingalpha.comNLSP NLS Pharmaceutics Ltd.January 20, 2024 | finance.yahoo.comNotice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 12, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing RequirementsDecember 23, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider TradesDecember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary SharesDecember 5, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and DatesDecember 1, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.November 27, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaNovember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary Shares NLSPNovember 16, 2023 | msn.comWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% TodayNovember 16, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanOctober 19, 2023 | finance.yahoo.comNLS Pharmaceuticals to Reschedule Company Update on Strategic DiscussionsOctober 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Company Update on Strategic PartnershipsSee More Headlines Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/06/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book0.47Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alexander Zwyer M.B.A. (Age 55)President, CEO & Director Comp: $1.07MDr. George Apostol M.D. (Age 51)Chief Medical Officer and Global Head of Research & Development Comp: $154kDr. Eric Konofal M.D. (Age 57)Ph.D., Co-Founder & Chief Scientific Officer Ms. Elena Thyen-PighinChief Financial OfficerDr. Christian C. Wenger Dr. iur. (Age 60)L.L.M., Ph.D., General Counsel Key CompetitorsPalisade BioNASDAQ:PALIHepion PharmaceuticalsNASDAQ:HEPAEntero TherapeuticsNASDAQ:ENTOTFF PharmaceuticalsNASDAQ:TFFPXenetic BiosciencesNASDAQ:XBIOView All Competitors NLSP Stock Analysis - Frequently Asked Questions Should I buy or sell NLS Pharmaceutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLSP, but not buy additional shares or sell existing shares. View NLSP analyst ratings or view top-rated stocks. How have NLSP shares performed in 2024? NLS Pharmaceutics' stock was trading at $0.5899 at the beginning of the year. Since then, NLSP shares have decreased by 77.5% and is now trading at $0.1325. View the best growth stocks for 2024 here. Are investors shorting NLS Pharmaceutics? NLS Pharmaceutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 45,400 shares, an increase of 182.0% from the April 30th total of 16,100 shares. Based on an average trading volume of 839,800 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the shares of the company are short sold. View NLS Pharmaceutics' Short Interest. When is NLS Pharmaceutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our NLSP earnings forecast. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NLSP) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.